21 November 2018
Researchers have uncovered a brand new role mitochondria play in keeping cancer cells alive and proliferating, new research out this week says. Published in the high-impact leading international journal Cell Metabolism, the research increases our understanding of the role of mitochondria in tumour formation, opening up new targets for treatment and research.
Mitochondria are essential components of all living cells, providing the fuel needed for cells to grow and function. Extending their landmark 2015 research showing that cancer cells with damaged mitochondria acquire replacement mitochondria from surrounding healthy cells to restore function, the researchers find that it’s not only the mitochondria’s energy- producing abilities cancer cells covet, but something much more unexpected.
“Previously, we thought of mitochondria solely as energy powerhouses,” says Professor Mike Berridge, head of the cancer cell biology programme at the Malaghan Institute and one of the senior authors of this research. “When cancer cells are deprived of their mitochondrial energy-producing function, they acquire replacement mitochondria from their environment. While that’s certainly important for keeping cells alive, we know cancer cells can generate small amounts of energy independently of their mitochondria – enough to grow and divide.
“Quite unexpectedly we found that, in addition to generating energy, mitochondria are also essential for making precursors of nucleic acids – the building blocks of our DNA. This is game-changing. While many cancer cells can survive without the energy from mitochondria, they simply cannot grow without the ability to form new strands of DNA, which we now know mitochondria play a vital role in.”
While the ability to recover energy-production is an important coping mechanism in cancer’s dogged resistance to drugs and treatments, being able to make new DNA is much more important in terms of a cell’s ability to grow, divide and spread. In a cancer setting this means the ability to form tumours. The research, which was the collaborative efforts of nearly 50 researchers spread across eight countries including New Zealand, opens the door for a new class of therapies that more accurately target this Achille’s heel of cancer.
“Not only does this work give us invaluable insight into the biology of cancer, it goes further and opens up a key target for cancer treatment,” says Prof Berridge, who was the only New Zealander associated with this publication. “If this property of mitochondria can be targeted effectively it opens the door for new types of combination cancer therapies. Such a drug is already used to treat arthritis, suggesting that refinement and repurposing may be possible.
Without the ability to synthesize new DNA these cells would be much more sensitive to treatment and just won’t be able to form tumours.”
The published paper can be viewed here:
In focus: Overcoming hurdles facing CAR T-cell therapy
19 January 2022
New study opens doors for immunotherapies for prostate cancer
13 December 2021
Professor Mike Berridge: winner of the Shorland Medal
15 November 2021
Taking RNA technology into NZ’s future
19 October 2021
New partnership to scale up CAR T-cell cancer treatment in New Zealand
23 September 2021
Building better CAR T-cell technology
3 May 2021